Tonira Pharma [Merged] Peer Comparison

BSE: 530155

₹19.75

₹0.25 (1.28%)

As on 29-May-2012IST

Market cap

₹16 Cr

Revenue (TTM)

₹34 Cr

P/E Ratio

--

P/B Ratio

1.6

Div. Yield

0 %

Edit

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	16	31,863	30,485	28,611	27,284
Revenue (₹ Cr)	34	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-3.36	414.00	288.22	-371.81	387.35
Net Margin (%)	-9.63	11.23	14.79	-3.93	26.01
RoE (%)	-35.39	8.38	29.77	-3.85	25.18
Price to Earnings	--	77.90	105.77	--	70.64
Price-To-Book	1.58	6.33	22.71	3.57	15.78

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	30.18	3,751.24	21.05	--	27.82
Total Income	31.81	3,903.86	21.47	--	28.52
Total Expenditure	27.80	2,835.28	15.03	--	25.24
EBITDA	2.39	915.96	6.02	--	2.57
Depreciation	3.07	116.62	1.79	--	0.73
EBIT	-0.69	799.34	4.23	--	1.84
Interest	3.14	267.10	1.27	--	0.63
Other Income	1.62	152.62	0.42	--	0.70
Exceptional Items	--	-580.51	--	--	--
Profit before Tax	-2.20	104.35	3.38	--	1.91
Provision for Tax	-0.12	8.65	1.00	--	0.66
Profit after Tax	-2.08	95.70	2.38	--	1.26

Liabilities (₹ Cr)

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	12.18	943.10	34.96	--	4.76
Minority Interest	0.00	--	--	--	--
Non-Current Liabilities	35.86	2,943.95	6.74	--	7.05
Current Liabilities	6.63	1,919.01	14.88	--	8.28
Total Liabilities	55.53	5,880.91	56.58	--	20.22

Assets (₹ Cr)

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	24.81	3,903.85	45.59	--	6.10
Current Assets	29.85	1,902.21	11.00	--	13.99
Total Assets	55.53	5,880.91	56.58	--	20.22
Total Debt*	36.73	3,851.66	14.89	--	7.18
Net Current Assets	23.22	-16.80	-3.88	--	5.71
Contingent Liabilities	79.27	503.13	0.62	--	--

Cashflow (₹ Cr)

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-0.93	641.81	5.64	--	--
Cash Flow from Investing Activities	-2.63	-276.61	-4.90	--	--
Cash from Financing Activities	2.71	-372.99	-1.13	--	--
Net Cash Inflow / Outflow	-0.86	-7.79	-0.40	--	--

Ratios

Profitability Ratios

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	1.98	7.83	9.33	--	25.13
ROE (%)	-15.74	95.20	14.88	--	30.45
ROA (%)	-3.87	1.67	4.20	--	7.45
EBIT Margin (%)	13.27	28.49	30.59	--	11.78
Net Margin (%)	-6.54	2.45	11.06	--	4.40
Cash Profit Margin (%)	3.27	5.65	19.78	--	6.67

Growth Ratios

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-18.12	-16.67	0.00	--	43.96
EBIT Growth (%)	-43.31	33.59	--	--	35.96
Net Profit Growth (%)	-303.57	109.55	0.00	--	32.56
EPS Growth (%)	-303.57	109.05	0.00	--	32.56
Book Value Growth (%)	-14.59	6,150.47	0.00	--	36.01

Valuation Ratios

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	36.13	0.00	--	0.00
Price / Book Value	1.22	17.93	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	12.31	7.17	5.48	--	2.62
Market Cap (₹ Cr)	14.82	3,548.59	0.00	--	0.00

Solvency Ratios

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	3.02	4.08	0.43	--	1.51
Short term debt to equity ratio	--	0.41	0.12	--	--
Current Ratio	4.50	0.99	0.74	--	1.69
Quick Ratio	2.16	0.62	0.74	--	1.32
Interest Coverage	0.30	1.39	3.66	--	4.02

Operating Efficiency Ratios

	Tonira Pharma [Merged]	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	12.63	16.13	38.72	--	29.17
Asset Turnover	0.57	0.65	0.37	--	1.77
Receivable days	60.87	57.31	141.31	--	88.98
Inventory Days	163.75	71.89	0.00	--	27.75
Payable days	71.44	104.96	535.25	--	122.14
Cash Conversion Cycle	153.18	24.24	-393.94	--	-5.40

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.